Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)

被引：24
|
作者：
Hu, M. [1 ]
Subbiah, V. [2 ]
Wirth, L. J. [3 ]
Schuler, M. [4 ,5 ]
Mansfield, A. S. [6 ]
Brose, M. S. [7 ]
Curigliano, G. [8 ,9 ,10 ]
Leboulleux, S. [11 ]
Zhu, V. W. [12 ]
Keam, B. [13 ]
Matos, I. [14 ]
Lin, C-C. [15 ]
Adkins, D. [16 ]
Baik, C. S. [17 ]
Lopes, G. [18 ]
Godbert, Y. [19 ]
Sarker, D. [20 ]
Zhang, H. [21 ]
Turner, C. [21 ]
Taylor, M. [22 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[4] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[5] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany
[6] Mayo Clin, Div Med Oncol, Rochester, MN USA
[7] Univ Penn, Abramson Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA
[8] IRCCS, Dept Oncol, European Inst Oncol, Milan, Italy
[9] IRCCS, Dept Hematooncol, European Inst Oncol, Milan, Italy
[10] Univ Milan, Milan, Italy
[11] Gustave Roussy, Med Nucl & Endocrine Oncol, Villejuif, France
[12] Univ Calif Irvine, Dept Med, Orange, CA 92668 USA
[13] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[14] Vall dHebron Inst Oncol, Early Drug Dev Unit, Barcelona, Spain
[15] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[16] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[17] Univ Washington, Sch Med, Thorac Head & Neck Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA
[18] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[19] Bergonie Inst Canc Ctr, Nucl Med, Bordeaux, France
[20] Kings Coll London, Dept Med Oncol, Guys Hosp, London, England
[21] Blueprint Med Corp, Cambridge, MA USA
[22] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1913O
引用
收藏
页码：S1084 / S1084
页数：1
相关论文
共 45 条
  • [31] Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
    Paz-Ares, L.
    Tan, E. H.
    Zhang, L.
    Hirsh, V.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C-H.
    Mok, T. S. K.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Laurie, S.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010)
    Roylance, Rebecca
    Kilburn, Lucy
    Kernaghan, Sarah
    Wardley, Andrew M.
    Macpherson, Iain
    Baird, Richard D.
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Ring, Alistair
    Bliss, Judith M.
    Turner, Nicholas
    CANCER RESEARCH, 2020, 80 (04)
  • [33] Results from a phase II trial of pembrolizumab (P) plus gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study
    de la Cruz-Merino, L.
    Cruz, J.
    Alonso, J. L.
    Quiroga Garcia, V.
    Moreno Anton, F.
    Andres, R.
    Santiesteban, M.
    Ramos Vazquez, M.
    Gion Cortes, M.
    Cortes, J.
    Palazon Carrion, N.
    Ceballos Lenza, I.
    Soto, A.
    Casas, M.
    Benito, S.
    Bezares Montes, S.
    Holgado, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
    Zhou, Caicun
    Wu, Yi Long
    Liu, Xiaoqing
    Wang, Changli
    Chen, Gongyan
    Feng, Ji Feng
    Zhang, Shucai
    Wang, Jie
    Zhou, Songwen
    Ren, Shengxiang
    Lu, Shun
    Zhang, Li
    Hu, Cheng-ping
    Luo, Yi
    Chen, Lei
    Ye, Ming
    Huang, Jianan
    Zhi, Xiuyi
    Zhang, Yiping
    Xiu, Qingyu
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
    Schuler, M.
    Tan, E-H.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T. S. K.
    Hirsh, V.
    Yang, J. C-H.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Arvis, C. Dubos
    Kolbeck, K.
    Massey, D.
    Fan, J.
    Paz-Ares, L.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] Repotrectinib in patients (pts) from Asia and China with ROS1 fusion- positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial
    Lu, S.
    Hu, X.
    Kim, S-W.
    Goto, K.
    Yang, N.
    Soo, R. A.
    Fang, J.
    Yao, W.
    Lee, K. H.
    Lim, D. W-T.
    Kato, T.
    Tamiya, M.
    Wu, J.
    Zhang, Y.
    Zhou, J.
    Ades, F.
    Hua, J.
    Wang, P. T.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1704 - S1704
  • [37] Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening (CRUK/15/010)
    Wardley, Andrew M.
    Kilburn, Lucy
    Kernaghan, Sarah
    Macpherson, Iain
    Baird, Richard D.
    Roylance, Rebecca
    Stephens, Peter
    Oikonomidou, Olga
    Braybrooke, Jeremy P.
    Tuthill, Mark
    Abraham, Jacinta
    Winter, Matthew C.
    Kingston, Belinda
    Wilkinson, Katie
    Bliss, Judith M.
    Ring, Alistair
    Turner, Nicholas
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Neoadjuvant Sunitinib (S) Administered with Weekly Paclitaxel (P)/Carboplatin(C) in Patients (Pts) with Locally Advanced Triple-Negative Breast Cancer (TNBC): Preliminary Results from a Phase I/II Trial of the Sarah Cannon Research Institute.
    Yardley, D. A.
    Barton, J.
    Hendricks, C.
    Webb, C.
    Priego, V.
    Nimeh, N.
    Gravenor, D.
    Shastry, M.
    Chirwa, T.
    Burris, H. A.
    CANCER RESEARCH, 2012, 72
  • [39] Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).
    Park, Keunchil
    Lee, Jong-Seok
    Lee, Ki Hyeong
    Kim, Joo-Hang
    Min, Young Joo
    Cho, Jae Yong
    Han, Ji-Youn
    Kim, Bong-Seog
    Kim, Jin-Soo
    Lee, Dae Ho
    Kang, Jin Hyoung
    Cho, Eun Kyung
    Jang, In-Jin
    Jung, Jina
    Kim, Hyo-Yeon
    Sin, Hui Jung
    Son, Jeewoong
    Woo, Jong Soo
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
    Lin, N. U.
    Borges, V. F.
    Patel, M. R.
    Okera, M.
    Meisel, J.
    Wesolowski, R.
    Pluard, T.
    Miller, K. D.
    McCarthy, N. J.
    Conlin, A. K.
    Mahtani, R.
    Sabanathan, D.
    McCann, K. E.
    Roesch, E.
    Mathauda-Sahota, G.
    Schroeder, J.
    Hamilton, E. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S338 - S338
12345